Interpretation of 2020 American College of Rheumatology Guideline for the Management of Gout from the Perspective of General Practitioners

doi:10.12114/j.issn.1007-9572.2021.00.133

Abstract

Abstract: The recent updates of guidelines for the management of gout have gradually promoted the standardization of gout diagnosis and treatment. What's more，the newly released 2020 American College of Rheumatology Guideline for the Management of Gout has made some vague concepts to be clear. As general practitioners play a vital role in the management of gout，a common and frequently-occurring disease，we interpreted the 2020 American College of Rheumatology Guideline for the Management of Gout from their perspective，and compared it to the latest Chinese guideline for the management of gout，offering proposal ideas to help general practitioners with the diagnosis and treatment of gout.

Key words: Gout, Hyperuricemia, Guideline, General practitioner

摘要：

近年来，国内外痛风治疗指南不断更新，使痛风诊治逐渐变得规范。随着《2020年美国风湿病学会痛风治疗指南》的公布，一些模糊的概念越来越清晰。痛风作为一种常见病、多发病，全科医生在痛风的治疗中起着至关重要的作用。本文将从全科医生的角度论述《2020年美国风湿病学会痛风治疗指南》，并与我国最新版痛风治疗指南进行对比，为全科医生诊治痛风提供参考建议。

关键词: 痛风, 高尿酸血症, 指南, 全科医生

LIU Min,MENG Juan. Interpretation of 2020 American College of Rheumatology Guideline for the Management of Gout from the Perspective of General Practitioners　[J]. Chinese General Practice, 2021, 24(25): 3148-3153. DOI: 10.12114/j.issn.1007-9572.2021.00.133.
刘敏,孟娟. 基于全科医生视角的《2020年美国风湿病学会痛风治疗指南》解读[J]. 中国全科医学, 2021, 24(25): 3148-3153. DOI: 10.12114/j.issn.1007-9572.2021.00.133.

References

［1］中华医学会内分泌学分会. 中国高尿酸血症与痛风诊疗指南（2019）［J］. 中华内分泌代谢杂志，2020，36（1）：1-12. DOI：10.3760/cma.j.issn.1000-6699.2020.01.001.
Chinese Society of Endocrinology. Guideline for the Diagnosis and Management of Hyperuricemia and Gout in China（2019）［J］. Chinese Journal of Endocrinology and Metabolism，2020，36（1）：1-12. DOI：10.3760/cma.j.issn.1000-6699.2020.01.001.
［2］FITZGERALD J D，DALBETH N，MIKULS T，et al. 2020 American College of Rheumatology Guideline for the Management of Gout［J］. Arthritis Care Res（Hoboken），2020，72（6）：744-760. DOI：10.1002/acr.24180.
［3］CAMPION E W，GLYNN R J，DELABRY L O. Asymptomatic hyperuricemia risks and consequences in the normative aging study［J］. Am J Med，1987，82（3）：421-426.
［4］KHANNA D，KHANNA P P，FITZGERALD J D，et al. 2012 American College of Rheumatology Guidelines for Management of Gout. Part 1：systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia［J］. Arthritis Care Res（Hoboken），2012，64（10）：1431-1446.
［5］中华医学会. 痛风及高尿酸血症基层诊疗指南（2019年）［J］. 中华全科医师杂志，2020，19（4）：293-303. DOI：10.3760/cma.j.cn114798-20200328-00382.
［6］邹和建. 强基层，提升痛风诊疗水平［J］. 中华全科医师杂志，2020，19（4）：288-289. DOI：10.3760/cma.j.cn114798-20200330-00389.
［7］WHITE W B，SAAG K G，BECKER M A，et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout［J］. N Engl J Med，2018，378（13）：1200-1210. DOI：10.1056/NEJMoa1710895.
［8］YAMMANAKA H，TAMAKI S，IDE Y，et al. Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy：results from FORTUNE-1，a prospective，multicentre randomised study［J］. Ann Rheum Dis，2018，77（2）：270-276. DOI：10.1136/annrheumdis-2017-211574.
［9］ MICHELLE H，ALISON C，STEWART C，et al. The British Society for Rheumatology Guideline for the Management of Gout［J］. Rheumatology，2017，56（7）：1056-1059.
［10］HILL E M，SKY K，SIT M，et al. Does starting allopurinol prolong acute treated gout? A randomized clinical trial［J］. Clin Rheumatol，2015，21（3）：120-125. DOI：10.1097/RHU.0000000000000235.
［11］TAYLOR T H，MECCHELLA J N，LARSON R J，et al. Initiation of allopurinol at first medical contact for acute attacks of gout：a randomized clinical trial［J］. Am J Med，2012，125（11）：1126-1134. DOI：10.1016/j.amjmed.2012.05.025.
［12］DOHERTY M，JENKINS W，RICHARDSON H，et al. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout：a randomised controlled trial ［J］. Lancet，2018，392（10156）：1403-1412. DOI：10.1016/S0140-6736(18)32158-5.
［13］CHEN C H，CHEN C B，CHANG C J，et al. Hypersensitivity and cardiovascular risks related to allopurinol and febuxostat therapy in Asians：a population-based cohort study and meta-analysis［J］. Clinical Pharmacology and Therapeutics，2019，106（2）：391-401. DOI：10.1002/CPT.1377.
［14］MOHAMED O，CARL S，LI J，et al. Dipstick spot urine pH does not accurately represent 24 hour urine pH measured by an electrode［J］. Int Braz J Urol，2016，42（3）：546-549. DOI：10.1590/S1677-5538.IBJU.2015.0071.
［15］YU K H，CHEN D Y，CHEN J H，et al. Management of Gout and Hyperuricemia：Multidisciplinary Consensus in Taiwan［J］. International Journal of Rheumatic Diseases，2018，21（4）：772-787. DOI：10.1111/1756-185x.13266.
［16］PEREZ-RUIZ F，CALABOZO M，PIJOAN J I，et al. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout［J］. Arthritis Rheum，2002，47（4）：356-360. DOI：10.1002/art.10511.
［17］史晓飞，徐东，帅宗文，等. 痛风相关知识问答（二）：痛风急性发作期及预防发作治疗篇［J］. 中华内科杂志，2018，57（10）：759-760. DOI：10.3760/cma.j.issn.0578-1426.2018.10.013.
［18］CHOI H K，ATKINSON K，KARLSON E W，et al. Obesity，weight change，hypertension，diuretic use，and risk of gout in men［J］. Arch Intern Med，2005，165（7）：742-748. DOI：10.1001/archinte.165.7.742.
［19］WALDMAN B，ANSQUER J C，SULLIVAN D R，et al. Effect of fenofibrate on uric acid and gout in type 2 diabetes：a post-hoc analysis of the randomised，controlled FIELD study［J］. Lancet Diabetes Endocrinol，2018，6（4）：310-318. DOI：10.1016/S2213-8587(18)30029-9.

[1]	ZHOU Penglong, CHANG Jing, DING Suying, CHEN Jingfeng, WANG Tao, LI Chenyang. Correlation Analysis between Age-Stratified Differences in Fat-to-muscle Ratio and Hyperuricemia [J]. Chinese General Practice, 2025, 28(27): 3375-3384.
[2]	CUI Yiyuan, YAN Yijing, WANG Ying, MENG Xiangju, ZHANG Qinglin, LIU Lixing, LI Sicong, FENG Li, The Working Group for the Clinical Practice Guideline for the Cancer-related Fatigue with Integrated Traditional Chinese and Western Medicine. Clinical Practice Guideline for the Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment of Cancer-related Fatigue [J]. Chinese General Practice, 2025, 28(27): 3345-3358.
[3]	ZHI Congcong, LI Xue, CHENG Yicheng, WANG Xiaolong, ZHENG Lihua. Guidelines for Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment of Hemorrhoids (2025 Edition) [J]. Chinese General Practice, 2025, 28(26): 3217-3228.
[4]	YANG Jiang, LI Jiansheng, CHEN Yaolong, LIU Huiguo, WANG Jianxin, YU Jiajie, LI Huiru, XIAO Qionghua, XIE Yang, LI Suyun, WANG Minghang. Guideline on Treating Adult Community-acquired Pneumonia with Chinese Patent Medicines (2025 Edition) [J]. Chinese General Practice, 2025, 28(20): 2464-2480.
[5]	CAO Qinhan, ZHUO Xiao, XIA Yuhan, CHE Yangxi, CHEN Min. Interpretation of Updated NCCN Clinical Guidelines for Rectal Cancer (2024.V1/V2) [J]. Chinese General Practice, 2025, 28(17): 2070-2074.
[6]	XIA Yuhan, ZHUO Xiao, CAO Qinhan, LIAO Xingyu, LUO Guoliang, TANG Taichun, CHEN Min. Interpretation of the Updated NCCN Clinical Practice Guidelines for Colon Cancer (2024.V4) [J]. Chinese General Practice, 2025, 28(14): 1689-1693.
[7]	MA Guifen, ZHANG Qian, SUN Jing. Interpretation of the Key Updates in the Latest Version of 2024 NCCN Clinical Practice Guidelines for Gastric Cancer [J]. Chinese General Practice, 2025, 28(14): 1681-1688.
[8]	Chinese Academy Society of Sleep Medicine, Chinese Medical Doctor Association, Sleep Medicine Group, China Neurologist Association. Chinese Guideline for Diagnosis and Treatment of Co-morbid Insomnia and Obstructive Sleep Apnea (2024) [J]. Chinese General Practice, 2025, 28(11): 1289-1303.
[9]	YAO Dingye, LUO Guiping, SUN Junsheng, REN Jingjing. Diagnosis and Treatment of Halitosis: a General Practice Perspective [J]. Chinese General Practice, 2025, 28(07): 900-904.
[10]	MA Hongyang, YUE Anna, SUN Kangyun. Familial Hypercholesterolemia: Diagnostic Differences between Domestic and Foreign Guidelines [J]. Chinese General Practice, 2025, 28(06): 655-665.
[11]	FANG Xiang, SONG Haiqi, LIAO Xiaoyang, LIU Lidi, ZHANG Peng, JIA Yu, YANG Ziyu, YANG Rong, LIU Ruhui. Recommendations for the Management of Hypertensive Disorders of Pregnancy in China: Based on the A Summary of the 2023 Society of Obstetric Medicine of Australia and New Zealand Hypertension in Pregnancy Guideline [J]. Chinese General Practice, 2025, 28(06): 649-654.
[12]	NI Xiaojia, LIN Hao, LUO Xufei, KUANG Zhuoran, LIU Yunlan, GUO Jianwen, CHEN Yaolong, CAI Yefeng, Working Group of Clinical Practice Guideline for the Prevention and Treatment of Stroke with Integrated Traditional Chinese and Western Medicine. Clinical Practice Guideline for the Prevention and Treatment of Stroke with Integrated Traditional Chinese and Western Medicine (2023 Edition) [J]. Chinese General Practice, 2025, 28(05): 521-533.
[13]	Phillips William R., Sturgiss Elizabeth, Glasziou Paul, olde Hartman Tim C., Orkin Aaron M., Prathivadi Pallavi, Reeve Joanne, Russell Grant M., van Weel Chris. Improving the Reporting of Primary Care Research: Consensus Reporting Items for Studies in Primary Care—the CRISP Statement [J]. Chinese General Practice, 2025, 28(04): 385-392.
[14]	GAO Yicheng, YU Zijin, CAO Rui, LIU Zhihan, FANG Rui, LI Yuanyuan, DENG Yingjie, XIANG Wenyuan, FEI Yutong. Thinking and Methodological Suggestions of Empirical Research in the Development of Clinical Practice Guidelines [J]. Chinese General Practice, 2025, 28(04): 402-406.
[15]	PENG Tao, ZOU Chuan, ZENG Xin, ZHANG Yan, SHEN Jing. A Controlled Study of Salon-training Models Based on the Calgary-Cambridge Guidelines for Improving Patient-physician Communication Skills in General Practice [J]. Chinese General Practice, 2025, 28(01): 71-76.